Short-course TB treatment using sitafloxacin regimens
Part of Infections, Lungs & breathing clinical trials.
This study tests whether adding sitafloxacin to certain short tuberculosis (TB) treatment plans can cure TB faster while staying safe. You may be eligible if you have drug-susceptible lung TB and your TB bacteria are sensitive to several specific TB medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Have confirmed TB in the lungs, with positive sputum tests (or TB test like Xpert showing TB in sputum)
- Your TB bacteria must be sensitive to a required list of TB medicines, including sitafloxacin (and others like rifampin and isoniazid)
- You can give written consent to join the study
- Not have TB outside the lungs (no extra-pulmonary or spread-out/disseminated TB)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether you can take a shorter course of standard treatment for drug-sensitive pulmonary (lung) tuberculosis by using a higher dose of rifampicin. It may help some people finish treatment sooner, while doctors track how well the infection clears.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This trial tests a shorter treatment for TB that is resistant to the drug rifampicin but still sensitive to isoniazid. It may help people finish treatment sooner and with fewer side effects.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.